Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2364031 Target Snapshot

Cell membrane · SUBCELLULAR · Bacteria

Back to Search Search this target Browse approvals Evidence Card
537Compounds
1,237Assays
0Approved Drugs
46.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Cell membrane shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Use infection as the disease frame, then confirm a stable protein accession before cross-source reuse.

Review focus
Disease frame ready

Use infection as the disease frame, then confirm a stable protein accession before cross-source reuse.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
infection

Cell membrane shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with infection because it currently carries approved-linked support. Linked drugs include CHLORHEXIDINE GLUCONATE, COLISTIMETHATE SODIUM, DAPTOMYCIN, OMIGANAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cell membrane as ChEMBL target CHEMBL2364031. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cell membrane
SUBCELLULAR · Bacteria
As of 2026-09-13
ChEMBL target ID
CHEMBL2364031
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cell membrane still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why infection is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCell membrane
Target TypeSUBCELLULAR
OrganismBacteria
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCell membrane
UniProt AccessionN/A

Cell membrane

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cell membrane.

Review nameCell membrane
OrganismBacteria
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Cell membrane shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
infection
5 linked drugs · 5 direct · 5 efficacy
Linked drugCHLORHEXIDINE GLUCONATE
Linked drugCOLISTIMETHATE SODIUM
Linked drugDAPTOMYCIN
Linked drugOMIGANAN
Approved-linked Approved
Acanthamoeba keratitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugCHLORHEXIDINE GLUCONATE
Linked drugPOLIHEXANIDE
Approved-linked Approved
bacterial disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugCOLISTIMETHATE SODIUM
Linked drugDAPTOMYCIN
Approved-linked Approved
cystic fibrosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugCHLORHEXIDINE GLUCONATE
Linked drugCOLISTIMETHATE SODIUM
Approved-linked Approved
bacterial endocarditis
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPTOMYCIN
Approved-linked Approved
bacteriemia
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPTOMYCIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with infection because it currently carries approved-linked support. Linked drugs include CHLORHEXIDINE GLUCONATE, COLISTIMETHATE SODIUM, DAPTOMYCIN, OMIGANAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseinfection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC5025.0
EC5021.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5271959 7.16 EC50 70.0 Preclinical
CHEMBL4211294 7.03 EC50 94.0 Preclinical
CHEMBL5290770 6.85 EC50 140.0 Preclinical
CHEMBL5283188 6.8 EC50 160.0 Preclinical
CHEMBL5291484 6.8 EC50 160.0 Preclinical
CHEMBL5432995 6.06 IC50 870.0 Preclinical
CHEMBL5403488 5.96 IC50 1100.0 Preclinical
CHEMBL3261880 5.92 IC50 1200.0 Preclinical
CHEMBL5395162 5.72 IC50 1900.0 Preclinical
CHEMBL561057 5.64 IC50 2300.0 Clinical
Distribution

pChEMBL Value Distribution

3
5.0
4
5.5
1
6.0
3
6.5
2
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

1,248
Total Assays
21
Tested Compounds
3
Assay Types
Binding — 1,213 assays, 21 compounds
BAO Format Assays Compounds Avg pChEMBL
subcellular format 769 21 5.6
cell membrane format 428 0 —
assay format 16 0 —
Functional — 18 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
subcellular format 16 0 —
assay format 2 0 —
ADME — 17 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
subcellular format 17 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine